184 related articles for article (PubMed ID: 23226568)
1. Mortality of IgA nephropathy patients: a single center experience over 30 years.
Lee H; Kim DK; Oh KH; Joo KW; Kim YS; Chae DW; Kim S; Chin HJ
PLoS One; 2012; 7(12):e51225. PubMed ID: 23226568
[TBL] [Abstract][Full Text] [Related]
2. A validation study of crescents in predicting ESRD in patients with IgA nephropathy.
Zhang X; Shi S; Ouyang Y; Yang M; Shi M; Pan X; Lv J; Wang Z; Ren H; Shen P; Wang W; Zhang H; Xie J; Chen N
J Transl Med; 2018 May; 16(1):115. PubMed ID: 29724226
[TBL] [Abstract][Full Text] [Related]
3. Treatment effects of Chinese medicine (Yi-Qi-Qing-Jie herbal compound) combined with immunosuppression therapies in IgA nephropathy patients with high-risk of end-stage renal disease (TCM-WINE): study protocol for a randomized controlled trial.
Li S; Li JP
Trials; 2020 Jan; 21(1):31. PubMed ID: 31907076
[TBL] [Abstract][Full Text] [Related]
4. Mortality and renal outcome of primary glomerulonephritis in Korea: observation in 1,943 biopsied cases.
Lee H; Kim DK; Oh KH; Joo KW; Kim YS; Chae DW; Kim S; Chin HJ
Am J Nephrol; 2013; 37(1):74-83. PubMed ID: 23343855
[TBL] [Abstract][Full Text] [Related]
5. Mortality in IgA Nephropathy: A Nationwide Population-Based Cohort Study.
Jarrick S; Lundberg S; Welander A; Carrero JJ; Höijer J; Bottai M; Ludvigsson JF
J Am Soc Nephrol; 2019 May; 30(5):866-876. PubMed ID: 30971457
[TBL] [Abstract][Full Text] [Related]
6. Addition of eGFR and Age Improves the Prognostic Absolute Renal Risk-Model in 1,134 Norwegian Patients with IgA Nephropathy.
Knoop T; Vågane AM; Vikse BE; Svarstad E; Magnúsdóttir BT; Leh S; Varberg Reisæter A; Bjørneklett R
Am J Nephrol; 2015; 41(3):210-9. PubMed ID: 25872002
[TBL] [Abstract][Full Text] [Related]
7. Clinical outcomes and predictors for ESRD and mortality in primary GN.
Chou YH; Lien YC; Hu FC; Lin WC; Kao CC; Lai CF; Chiang WC; Lin SL; Tsai TJ; Wu KD; Chen YM
Clin J Am Soc Nephrol; 2012 Sep; 7(9):1401-8. PubMed ID: 22798538
[TBL] [Abstract][Full Text] [Related]
8. Natural history of immunoglobulin A nephropathy and predictive factors of prognosis: a long-term follow up of 204 cases in China.
Lv J; Zhang H; Zhou Y; Li G; Zou W; Wang H
Nephrology (Carlton); 2008 Jun; 13(3):242-6. PubMed ID: 18221258
[TBL] [Abstract][Full Text] [Related]
9. A novel simpler histological classification for renal survival in IgA nephropathy: a retrospective study.
Manno C; Strippoli GF; D'Altri C; Torres D; Rossini M; Schena FP
Am J Kidney Dis; 2007 Jun; 49(6):763-75. PubMed ID: 17533019
[TBL] [Abstract][Full Text] [Related]
10. The effects of cytotoxic therapy in progressive IgA nephropathy.
Shin JH; Lee JE; Park JH; Lim S; Jang HR; Kwon GY; Huh W; Jung SH; Kim YG; Oh HY; Kim DJ
Ann Med; 2016; 48(3):171-81. PubMed ID: 27031662
[TBL] [Abstract][Full Text] [Related]
11. Long-term prognosis of clinically early IgA nephropathy is not always favorable.
Lee H; Hwang JH; Paik JH; Ryu HJ; Kim DK; Chin HJ; Oh YK; Joo KW; Lim CS; Kim YS; Lee JP
BMC Nephrol; 2014 Jun; 15():94. PubMed ID: 24946688
[TBL] [Abstract][Full Text] [Related]
12. Serum immunoglobulin G provides early risk prediction in immunoglobulin A nephropathy.
Liu D; You J; Liu Y; Tang X; Tan X; Xia M; Wu L; Chen G; He L; Zhu X; Liu H
Int Immunopharmacol; 2019 Jan; 66():13-18. PubMed ID: 30415190
[TBL] [Abstract][Full Text] [Related]
13. Mortality in patients with IgA nephropathy.
Knoop T; Vikse BE; Svarstad E; Leh S; Reisæter AV; Bjørneklett R
Am J Kidney Dis; 2013 Nov; 62(5):883-90. PubMed ID: 23796906
[TBL] [Abstract][Full Text] [Related]
14. Long-term renal survival and undetected risk factors of IgA nephropathy in Chinese children-a retrospective 1243 cases analysis from single centre experience.
Wu H; Fang X; Xia Z; Gao C; Peng Y; Li X; Zhang P; Kuang Q; Wang R; Wang M
J Nephrol; 2020 Dec; 33(6):1263-1273. PubMed ID: 32507961
[TBL] [Abstract][Full Text] [Related]
15. Long-term renal survival and related risk factors in patients with IgA nephropathy: results from a cohort of 1155 cases in a Chinese adult population.
Le W; Liang S; Hu Y; Deng K; Bao H; Zeng C; Liu Z
Nephrol Dial Transplant; 2012 Apr; 27(4):1479-85. PubMed ID: 21965586
[TBL] [Abstract][Full Text] [Related]
16. Long-term outcomes of end-stage kidney disease for patients with IgA nephropathy: A multi-centre registry study.
Zhang L; Liu X; Pascoe EM; Badve SV; Boudville NC; Clayton PA; De Zoysa J; Hawley CM; Kanellis J; McDonald SP; Peh CA; Polkinghorne KR; Johnson DW
Nephrology (Carlton); 2016 May; 21(5):387-96. PubMed ID: 26393772
[TBL] [Abstract][Full Text] [Related]
17. Long-term outcome of IgA nephropathy with minimal change disease: a comparison between patients with and without minimal change disease.
Li XW; Liang SS; Le WB; Cheng SQ; Zeng CH; Wang JQ; Liu ZH
J Nephrol; 2016 Aug; 29(4):567-73. PubMed ID: 26537358
[TBL] [Abstract][Full Text] [Related]
18. Histopathologic features aid in predicting risk for progression of IgA nephropathy.
Walsh M; Sar A; Lee D; Yilmaz S; Benediktsson H; Manns B; Hemmelgarn B
Clin J Am Soc Nephrol; 2010 Mar; 5(3):425-30. PubMed ID: 20089495
[TBL] [Abstract][Full Text] [Related]
19. Clinical and prognostic significance of C1q deposition in IgAN patients-a retrospective study.
Tian S; Yang X; Luo J; Guo H
Int Immunopharmacol; 2020 Nov; 88():106896. PubMed ID: 33182045
[TBL] [Abstract][Full Text] [Related]
20. Primary IgA nephropathy in elderly patients.
Cheungpasitporn W; Nasr SH; Thongprayoon C; Mao MA; Qian Q
Nephrology (Carlton); 2015 Jun; 20(6):419-25. PubMed ID: 25726845
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
